[HER-2/neu oncogene in the selection of treatment for breast cancer and as a target of immunotherapy].
Isola
J
J
Tampereen yliopisto, Lääketieteellisen teknologian instituutti PL 607, 33101 Tampere. jorma.isola@uta.fi
Järvinen
T
T
Tanner
M
M
Holli
K
K
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000276:immunology*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab